Gossamer Bio, Inc. (GOSS) Files FDA NDA for Seralutinib in PAH
Gossamer Bio submitted a New Drug Application to the U.S. FDA for seralutinib to treat pulmonary arterial hypertension, supported by Phase 3 PROSERA and confirmatory Phase 2 TORREY data. FDA filing acceptance is pending later this year.Material DetailsContext by AI AnalystThis marks a late-stage mi…